FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
9/25/2023 12:42:33 PM | Chg. -0.070 | Volume | Bid12:43:34 PM | Ask12:43:34 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
30.440EUR | -0.23% | 19,457 Turnover: 593,884.170 |
30.440Bid Size: 450 | 30.450Ask Size: 410 | 17.18 bill.EUR | 3.02% | 12.50 |
GlobeNewswire
6/11/2021
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care
GlobeNewswire
11/11/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
11/4/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/29/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/23/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...
GlobeNewswire
6/9/2017
KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
GlobeNewswire
1/27/2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®